Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceutical products on a global basis. The Company's products are sold worldwide, primarily to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. It manufactures products in the United States, Puerto Rico and in eight foreign countries. In September 2009, BMS acquired Medarex, Inc., and in December 2009, it divested the Mead Johnson Nutrition Company. In October 2010, Novo Nordisk A/S completed divestment of ZymoGenetics to the Company.
Bristol-Myers Squibb has P/E ratio 13.66, Indicated annual dividend 1.32, Beta coefficient 0.62, Earning per share 1.94 and share outstanding 1,711,690,000.
Tidak ada komentar:
Posting Komentar